Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
October 03, 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Gives Back to Local Greater New Haven Community
September 30, 2022 09:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Bank of America Securities Precision Oncology Conference
September 26, 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Upcoming Investor Conferences
August 31, 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Changes to its Board of Directors
August 18, 2022 16:01 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations
August 15, 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Appoints John Northcott as Chief Commercial Officer
August 01, 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
June 02, 2022 16:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
June 01, 2022 08:00 ET
|
Arvinas Inc.
-- In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation – --...